サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1555609

ジェネリックオンコロジー薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2033年予測

Generic Oncology Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 176 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
ジェネリックオンコロジー薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2033年予測
出版日: 2024年09月09日
発行: Persistence Market Research
ページ情報: 英文 176 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界のジェネリックオンコロジー薬市場に関する包括的なレポートを発表し、市場促進要因・動向・機会・課題など、主要な市場ダイナミクスを詳細に分析しました。本レポートは、市場の構造と成長の可能性についての詳細な洞察を提供します。

主要な洞察

  • ジェネリックオンコロジー薬市場規模（2024E）：276億9,000万米ドル
  • 予測市場規模（2033F）：489億米ドル
  • 世界市場成長率（CAGR 2024～2033年）：6.5%

ジェネリックオンコロジー薬市場- レポート範囲：

ジェネリックオンコロジー薬は、その手頃な価格と様々ながんの治療効果により、ヘルスケア分野でますます重要性を増しています。これらの医薬品は、特に発展途上地域において、より多くの人々が利用できるようにすることで、ブランドがん治療に代わる不可欠な選択肢を提供しています。がん罹患率の上昇と費用対効果の高い治療へのニーズが、市場の重要な促進要因となっています。ジェネリックオンコロジー薬は、化学療法、免疫療法、標的療法など幅広いがん治療をカバーしており、市場の成長に貢献しています。

市場成長の促進要因：

世界のジェネリックオンコロジー薬市場の成長を後押ししている主な要因はいくつかあります。世界のがん罹患率の増加と、手頃な価格の治療オプションに対する需要の高まりが重要な促進要因となっています。政府やヘルスケア機関は患者の経済的負担の軽減に注力しており、これがジェネリックオンコロジー薬の需要をさらに押し上げています。さらに、主なブランド抗がん剤の特許切れにより、ジェネリック医薬品の開発・導入の機会が生まれています。また、ブランド薬に代わる効果的で安全な医薬品としてジェネリック医薬品に対する認識と受容が高まっていることも、市場拡大に寄与しています。

市場抑制要因：

大きな成長の可能性があるにもかかわらず、ジェネリック医薬品市場は課題に直面しています。主なハードルの1つは、ジェネリック医薬品の開発と承認に伴う複雑さとコストの高さで、新規参入企業の市場参入を遅らせる可能性があります。さらに、厳しい規制要件や知的財産権法によって、特定の地域ではジェネリック医薬品の入手が制限される可能性があります。さらに、ジェネリックオンコロジー薬の生物学的同等性や有効性に関する懸念は、先発医薬品と比較して市場成長に影響を与える可能性があります。

市場機会：

ジェネリックオンコロジー薬市場は、特に安価ながん治療へのアクセスが優先される新興市場において、大きなビジネスチャンスをもたらしています。これらの地域では、ヘルスケアインフラの整備やジェネリック医薬品の普及に向けた政府の取り組みに注目が集まっており、市場成長の原動力となることが期待されます。さらに、医薬品製造プロセスの進歩や、高価ながん治療の有力な代替品としてのバイオシミラー医薬品の探求は、市場拡大の新たな道を提供します。ジェネリック医薬品メーカーとヘルスケアプロバイダーとの戦略的提携により、これらの医薬品の入手可能性と採用がさらに促進されるであろう。

本レポートで扱う主な質問

  • 世界のジェネリックオンコロジー薬市場を牽引する主な要因は何か？
  • ジェネリック医薬品が最も多く採用されているがんの種類と地域は？
  • 規制の枠組みや特許切れは市場の競合情勢にどのような影響を与えているか？
  • ジェネリックオンコロジー薬市場の主要プレイヤーは誰で、どのような戦略で市場での地位を維持しているのか？
  • 世界のジェネリック医薬品市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 重要成功要因

  • 製品採用分析
  • 使用状況分析- 主要統計
  • バリューチェーン分析
  • 最近の製品承認/発売
  • 主な規制- 地域別
  • 製品のUSP分析
  • パイプライン評価

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 分子タイプ別
    • 投与経路別
    • 流通チャネル別
    • 地域別
  • 2024年の市場シナリオ

第7章 世界のジェネリックオンコロジー薬市場の需要（金額、10億米ドル）分析

  • 市場金額（10億米ドル）分析、2019～2023年
  • 市場金額（10億米ドル）予測、2024～2033年
    • 前年比成長動向分析
    • 絶対的収益機会

第8章 分子タイプ別：世界のジェネリックオンコロジー薬市場分析

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 大分子
    • 低分子
  • 分子タイプ別の市場の魅力分析

第9章 投与経路別：世界のジェネリックオンコロジー薬市場分析

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 経口
    • 非経口
  • 投与経路別の市場の魅力分析

第10章 流通チャネル別：世界のジェネリックオンコロジー薬市場分析

  • イントロダクション/主な調査結果
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • マネージドケア機関
  • 流通チャネル別市場の魅力分析

第11章 地域別：世界のジェネリックオンコロジー薬市場分析

  • イントロダクション
  • 市場規模（10億米ドル）分析、2019～2023年
  • 市場規模（10億米ドル）分析と予測、2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ（中東・アフリカ）
  • 地域別市場の魅力分析

第12章 北米のジェネリックオンコロジー薬市場分析

第13章 ラテンアメリカのジェネリックオンコロジー薬市場分析

第14章 欧州のジェネリックオンコロジー薬市場分析

第15章 東アジアのジェネリックオンコロジー薬市場分析

第16章 南アジアのジェネリックオンコロジー薬市場分析

第17章 オセアニアのジェネリックオンコロジー薬市場

第18章 中東およびアフリカのジェネリックオンコロジー薬市場分析

第19章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場集中
  • 市場プレゼンス分析

第20章 競合分析

  • 競合ダッシュボード
  • 競合の詳細
    • Bausch Health Companies Inc.
    • Novartis
    • Pfizer
    • GSK
    • Celgene
    • Teva Pharmaceuticals
    • Merck &Company
    • Aurobindo Pharma
    • Hikma Pharmaceuticals
    • Mylan
    • NATCO Pharma

第21章 使用される前提条件と頭字語

第22章 調査手法

目次
Product Code: PMRREP25480

Persistence Market Research has recently released a comprehensive report on the global Generic Oncology Drugs Market, providing an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges. This report offers detailed insights into the market's structure and growth potential.

Key Insights:

  • Generic Oncology Drugs Market Size (2024E): USD 27.69 Bn
  • Projected Market Value (2033F): USD 48.9 Bn
  • Global Market Growth Rate (CAGR 2024 to 2033): 6.5%

Generic Oncology Drugs Market - Report Scope:

Generic oncology drugs are becoming increasingly critical in the healthcare sector due to their affordability and effectiveness in treating various cancers. These drugs provide an essential alternative to branded cancer treatments, making them accessible to a larger population, especially in developing regions. The rising incidence of cancer, coupled with the need for cost-effective treatments, is a significant driver of the market. Generic oncology drugs cover a broad spectrum of cancer treatments, including chemotherapy, immunotherapy, and targeted therapies, contributing to the market's growth.

Market Growth Drivers:

Several key factors are driving the growth of the global generic oncology drugs market. The increasing prevalence of cancer worldwide and the rising demand for affordable treatment options are crucial drivers. Governments and healthcare organizations are focusing on reducing the financial burden on patients, which is further boosting the demand for generic oncology drugs. Additionally, patent expirations of key branded cancer drugs are creating opportunities for the development and introduction of generic alternatives. The growing awareness and acceptance of generic medicines as effective and safe alternatives to branded drugs are also contributing to market expansion.

Market Restraints:

Despite its significant growth potential, the generic oncology drugs market faces challenges. One of the primary hurdles is the complexity and high cost associated with the development and approval of generic oncology drugs, which can slow down market entry for new players. Furthermore, strict regulatory requirements and intellectual property laws can limit the availability of generics in certain regions. Additionally, concerns related to the bioequivalence and efficacy of generic oncology drugs compared to their branded counterparts can impact market growth.

Market Opportunities:

The generic oncology drugs market presents substantial opportunities, particularly in emerging markets where access to affordable cancer treatment is a priority. The increasing focus on healthcare infrastructure development and government initiatives to promote generic drugs in these regions is expected to drive market growth. Moreover, advancements in drug manufacturing processes and the exploration of biosimilar drugs as a viable alternative for expensive cancer treatments offer new avenues for market expansion. Strategic collaborations between generic drug manufacturers and healthcare providers will further enhance the availability and adoption of these drugs.

Key Questions Answered in the Report:

  • What are the primary factors driving the global generic oncology drugs market?
  • Which cancer types are seeing the highest adoption of generic oncology drugs, and in which regions?
  • How are regulatory frameworks and patent expirations influencing the competitive landscape of this market?
  • Who are the leading players in the generic oncology drugs market, and what strategies are they using to maintain their market positions?
  • What are the emerging trends and future prospects in the global generic oncology drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global generic oncology drugs market, such as Teva Pharmaceuticals, Mylan N.V., and Fresenius Kabi, are focusing on innovation, product expansion, and strategic partnerships to strengthen their positions. These companies are heavily investing in research and development to improve drug formulations, expand their oncology portfolios, and ensure compliance with stringent regulatory standards. Collaborations with hospitals and healthcare systems are essential for market penetration, particularly in high-growth regions. As the demand for affordable cancer treatment continues to rise, companies in this space are prioritizing quality, efficacy, and availability to ensure long-term success in the generic oncology drugs market.

Key Companies Profiled:

  • Bausch Health Companies Inc.
  • Novartis
  • Pfizer
  • GSK
  • Celgene
  • Teva Pharmaceuticals
  • Merck & Company
  • Aurobindo Pharma
  • Hikma Pharmaceuticals
  • Mylan
  • NATCO Pharma

Key Segments Covered in Generic Oncology Drugs Industry Research

Molecule:

  • Large Molecule
  • Small Molecule

Route of Administration:

  • Oral
  • Parenteral

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Managed Care Institutions

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption Analysis
  • 4.2. Usage Analysis - Key Statistics
  • 4.3. Value Chain Analysis
  • 4.4. Recent Product Approvals/Launches
  • 4.5. Key Regulations - By Region
  • 4.6. Product USP Analysis
  • 4.7. Pipeline Assessment

5. Market Background

  • 5.1. Macroeconomic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Overview
    • 5.1.3. Global Generic Drugs Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Prevalence of Cancer
    • 5.2.2. Increasing Generic Product Approvals
    • 5.2.3. Increasing Cases of Cancer Patients
    • 5.2.4. Mergers and Acquisitions
    • 5.2.5. Regulatory Policies
    • 5.2.6. Recent Product Approvals
    • 5.2.7. Product Pipeline
    • 5.2.8. Advertisements and Endorsements
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Molecule Type
    • 6.1.2. By Route of Administration
    • 6.1.3. By Distribution Channel
    • 6.1.4. By Region
  • 6.2. 2024 Market Scenario

7. Global Generic Oncology Drugs Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Molecule Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis, by Molecule Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Molecule Type, 2024-2033
    • 8.3.1. Large Molecule
    • 8.3.2. Small Molecule
  • 8.4. Market Attractiveness Analysis, by Molecule Type

9. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Attractiveness Analysis, by Route of Administration

10. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Distribution Channel, 2024-2033
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacies
    • 10.3.4. Managed Care Institutions
  • 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
  • 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. East Asia
    • 11.3.5. South Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis, by Region

12. North America Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Molecule Type
    • 12.3.3. By Route of Administration
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Molecule Type
    • 12.4.3. By Route of Administration
    • 12.4.4. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Generic Oncology Drugs Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 12.8.1.2.1. By Molecule Type
        • 12.8.1.2.2. By Route of Administration
        • 12.8.1.2.3. By Distribution Channel
    • 12.8.2. Canada Generic Oncology Drugs Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 12.8.2.2.1. By Molecule Type
        • 12.8.2.2.2. By Route of Administration
        • 12.8.2.2.3. By Distribution Channel

13. Latin America Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Mexico
      • 13.3.1.2. Brazil
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Molecule Type
    • 13.3.3. By Route of Administration
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Molecule Type
    • 13.4.3. By Route of Administration
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Mexico Generic Oncology Drugs Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.1.2.1. By Molecule Type
        • 13.8.1.2.2. By Route of Administration
        • 13.8.1.2.3. By Distribution Channel
    • 13.8.2. Brazil Generic Oncology Drugs Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.2.2.1. By Molecule Type
        • 13.8.2.2.2. By Route of Administration
        • 13.8.2.2.3. By Distribution Channel
    • 13.8.3. Argentina Generic Oncology Drugs Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.3.2.1. By Molecule Type
        • 13.8.3.2.2. By Route of Administration
        • 13.8.3.2.3. By Distribution Channel

14. Europe Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Russia
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Molecule Type
    • 14.3.3. By Route of Administration
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Molecule Type
    • 14.4.3. By Route of Administration
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Generic Oncology Drugs Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.1.2.1. By Molecule Type
        • 14.8.1.2.2. By Route of Administration
        • 14.8.1.2.3. By Distribution Channel
    • 14.8.2. Italy Generic Oncology Drugs Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.2.2.1. By Molecule Type
        • 14.8.2.2.2. By Route of Administration
        • 14.8.2.2.3. By Distribution Channel
    • 14.8.3. France Generic Oncology Drugs Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.3.2.1. By Molecule Type
        • 14.8.3.2.2. By Route of Administration
        • 14.8.3.2.3. By Distribution Channel
    • 14.8.4. U.K. Generic Oncology Drugs Market Analysis
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.4.2.1. By Molecule Type
        • 14.8.4.2.2. By Route of Administration
        • 14.8.4.2.3. By Distribution Channel
    • 14.8.5. Spain Generic Oncology Drugs Market Analysis
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.5.2.1. By Molecule Type
        • 14.8.5.2.2. By Route of Administration
        • 14.8.5.2.3. By Distribution Channel
    • 14.8.6. BENELUX Generic Oncology Drugs Market Analysis
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.6.2.1. By Molecule Type
        • 14.8.6.2.2. By Route of Administration
        • 14.8.6.2.3. By Distribution Channel
    • 14.8.7. Russia Generic Oncology Drugs Market Analysis
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.7.2.1. By Molecule Type
        • 14.8.7.2.2. By Route of Administration
        • 14.8.7.2.3. By Distribution Channel

15. East Asia Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Molecule Type
    • 15.3.3. By Route of Administration
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Molecule Type
    • 15.4.2. By Route of Administration
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Generic Oncology Drugs Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.1.2.1. By Molecule Type
        • 15.8.1.2.2. By Route of Administration
        • 15.8.1.2.3. By Distribution Channel
    • 15.8.2. Japan Generic Oncology Drugs Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.2.2.1. By Molecule Type
        • 15.8.2.2.2. By Route of Administration
        • 15.8.2.2.3. By Distribution Channel
    • 15.8.3. South Korea Generic Oncology Drugs Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.3.2.1. By Molecule Type
        • 15.8.3.2.2. By Route of Administration
        • 15.8.3.2.3. By Distribution Channel

16. South Asia Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Molecule Type
    • 16.3.3. By Route of Administration
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Molecule Type
    • 16.4.3. By Route of Administration
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Generic Oncology Drugs Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.1.2.1. By Molecule Type
        • 16.8.1.2.2. By Route of Administration
        • 16.8.1.2.3. By Distribution Channel
    • 16.8.2. Indonesia Generic Oncology Drugs Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.2.2.1. By Molecule Type
        • 16.8.2.2.2. By Route of Administration
        • 16.8.2.2.3. By Distribution Channel
    • 16.8.3. Malaysia Generic Oncology Drugs Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.3.2.1. By Molecule Type
        • 16.8.3.2.2. By Route of Administration
        • 16.8.3.2.3. By Distribution Channel
    • 16.8.4. Thailand Generic Oncology Drugs Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.4.2.1. By Molecule Type
        • 16.8.4.2.2. By Route of Administration
        • 16.8.4.2.3. By Distribution Channel

17. Oceania Generic Oncology Drugs Market 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Molecule Type
    • 17.3.3. By Route of Administration
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Molecule Type
    • 17.4.3. By Route of Administration
    • 17.4.4. By Distribution Channel
  • 17.5. Key Market Participants - Intensity Mapping
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. Australia Generic Oncology Drugs Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.1.2.1. By Molecule Type
        • 17.8.1.2.2. By Route of Administration
        • 17.8.1.2.3. By Distribution Channel
    • 17.8.2. New Zealand Generic Oncology Drugs Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.2.2.1. By Molecule Type
        • 17.8.2.2.2. By Route of Administration
        • 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkey
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Molecule Type
    • 18.3.3. By Route of Administration
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Molecule Type
    • 18.4.3. By Route of Administration
    • 18.4.4. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. GCC Countries Generic Oncology Drugs Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.1.2.1. By Molecule Type
        • 18.8.1.2.2. By Route of Administration
        • 18.8.1.2.3. By Distribution Channel
    • 18.8.2. Turkey Generic Oncology Drugs Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.2.2.1. By Molecule Type
        • 18.8.2.2.2. By Route of Administration
        • 18.8.2.2.3. By Distribution Channel
    • 18.8.3. South Africa Generic Oncology Drugs Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.3.2.1. By Molecule Type
        • 18.8.3.2.2. By Route of Administration
        • 18.8.3.2.3. By Distribution Channel
    • 18.8.4. North Africa Generic Oncology Drugs Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.4.2.1. By Molecule Type
        • 18.8.4.2.2. By Route of Administration
        • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

  • 19.1. Market Analysis, by Tier of Companies
  • 19.2. Market Share Analysis of Top Players
  • 19.3. Market Concentration
  • 19.4. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Deep Dive
    • 20.2.1. Bausch Health Companies Inc.
      • 20.2.1.1. Overview
      • 20.2.1.2. Product Portfolio
      • 20.2.1.3. Sales Footprint
      • 20.2.1.4. Key Financials
      • 20.2.1.5. SWOT Analysis
      • 20.2.1.6. Strategy Overview
        • 20.2.1.6.1. Marketing Strategy
        • 20.2.1.6.2. Product Strategy
        • 20.2.1.6.3. Channel Strategy
    • 20.2.2. Novartis
      • 20.2.2.1. Overview
      • 20.2.2.2. Product Portfolio
      • 20.2.2.3. Sales Footprint
      • 20.2.2.4. Key Financials
      • 20.2.2.5. SWOT Analysis
      • 20.2.2.6. Strategy Overview
        • 20.2.2.6.1. Marketing Strategy
        • 20.2.2.6.2. Product Strategy
        • 20.2.2.6.3. Channel Strategy
    • 20.2.3. Pfizer
      • 20.2.3.1. Overview
      • 20.2.3.2. Product Portfolio
      • 20.2.3.3. Sales Footprint
      • 20.2.3.4. Key Financials
      • 20.2.3.5. SWOT Analysis
      • 20.2.3.6. Strategy Overview
        • 20.2.3.6.1. Marketing Strategy
        • 20.2.3.6.2. Product Strategy
        • 20.2.3.6.3. Channel Strategy
    • 20.2.4. GSK
      • 20.2.4.1. Overview
      • 20.2.4.2. Product Portfolio
      • 20.2.4.3. Sales Footprint
      • 20.2.4.4. Key Financials
      • 20.2.4.5. SWOT Analysis
      • 20.2.4.6. Strategy Overview
        • 20.2.4.6.1. Marketing Strategy
        • 20.2.4.6.2. Product Strategy
        • 20.2.4.6.3. Channel Strategy
    • 20.2.5. Celgene
      • 20.2.5.1. Overview
      • 20.2.5.2. Product Portfolio
      • 20.2.5.3. Sales Footprint
      • 20.2.5.4. Key Financials
      • 20.2.5.5. SWOT Analysis
      • 20.2.5.6. Strategy Overview
        • 20.2.5.6.1. Marketing Strategy
        • 20.2.5.6.2. Product Strategy
        • 20.2.5.6.3. Channel Strategy
    • 20.2.6. Teva Pharmaceuticals
      • 20.2.6.1. Overview
      • 20.2.6.2. Product Portfolio
      • 20.2.6.3. Sales Footprint
      • 20.2.6.4. Key Financials
      • 20.2.6.5. SWOT Analysis
      • 20.2.6.6. Strategy Overview
        • 20.2.6.6.1. Marketing Strategy
        • 20.2.6.6.2. Product Strategy
        • 20.2.6.6.3. Channel Strategy
    • 20.2.7. Merck & Company
      • 20.2.7.1. Overview
      • 20.2.7.2. Product Portfolio
      • 20.2.7.3. Sales Footprint
      • 20.2.7.4. Key Financials
      • 20.2.7.5. SWOT Analysis
      • 20.2.7.6. Strategy Overview
        • 20.2.7.6.1. Marketing Strategy
        • 20.2.7.6.2. Product Strategy
        • 20.2.7.6.3. Channel Strategy
    • 20.2.8. Aurobindo Pharma
      • 20.2.8.1. Overview
      • 20.2.8.2. Product Portfolio
      • 20.2.8.3. Sales Footprint
      • 20.2.8.4. Key Financials
      • 20.2.8.5. SWOT Analysis
      • 20.2.8.6. Strategy Overview
        • 20.2.8.6.1. Marketing Strategy
        • 20.2.8.6.2. Product Strategy
        • 20.2.8.6.3. Channel Strategy
    • 20.2.9. Hikma Pharmaceuticals
      • 20.2.9.1. Overview
      • 20.2.9.2. Product Portfolio
      • 20.2.9.3. Sales Footprint
      • 20.2.9.4. Key Financials
      • 20.2.9.5. SWOT Analysis
      • 20.2.9.6. Strategy Overview
        • 20.2.9.6.1. Marketing Strategy
        • 20.2.9.6.2. Product Strategy
        • 20.2.9.6.3. Channel Strategy
    • 20.2.10. Mylan
      • 20.2.10.1. Overview
      • 20.2.10.2. Product Portfolio
      • 20.2.10.3. Sales Footprint
      • 20.2.10.4. Key Financials
      • 20.2.10.5. SWOT Analysis
      • 20.2.10.6. Strategy Overview
        • 20.2.10.6.1. Marketing Strategy
        • 20.2.10.6.2. Product Strategy
        • 20.2.10.6.3. Channel Strategy
    • 20.2.11. NATCO Pharma
      • 20.2.11.1. Overview
      • 20.2.11.2. Product Portfolio
      • 20.2.11.3. Sales Footprint
      • 20.2.11.4. Key Financials
      • 20.2.11.5. SWOT Analysis
      • 20.2.11.6. Strategy Overview
        • 20.2.11.6.1. Marketing Strategy
        • 20.2.11.6.2. Product Strategy
        • 20.2.11.6.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology